FEB 14, 2019 7:30 AM PST

Keynote Presentation: A Comparative Approach to Oncology Drug Development: Integrating Canine Models

Speaker

Abstract

Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and humans. In this presentation, you will learn about the intramural National Cancer Institute’s Comparative Oncology Program (COP) and Comparative Oncology Trials Consortium (COTC), which provide the necessary infrastructure and expertise in comparative oncology trial design and execution to support studies that are designed to advance and inform human cancer drug development. Several specific examples of how the approach has been applied to the development of novel small molecules, biologic agents, immune-oncology approaches will be presented. This presentation will illustrate how integration of comparative oncology studies can inform the process of drug development for human patients, and demonstrate the value of the approach for the drug development community/relevant stakeholders.

Learning Objectives: 

1. The audience will gain an appreciation and understanding of the value of spontaneous cancers that develop naturally in companion animals in studies of cancer biology and therapy;
2. The audience will gain an understanding of how comparative oncology clinical trials are conducted through the NCI’s Comparative Oncology Trials Consortium to address specific drug development questions, which are complementary to the conventional preclinical testing carried out in other animal models and to Phase 1-2 data collected from human patients.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
OCT 07, 2021 10:00 AM PDT
C.E. CREDITS
OCT 07, 2021 10:00 AM PDT
Date: October 07, 2021 Time: 10:00am (PDT), 1:00pm (EDT) It's estimated than less than 10% of investigational anti-cancer drugs successfully achieve FDA approval for clinical use. This i...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
FEB 14, 2019 7:30 AM PST

Keynote Presentation: A Comparative Approach to Oncology Drug Development: Integrating Canine Models



Show Resources
Loading Comments...
Show Resources